Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice

Cyp2d6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants—a pilot study

Rau, T. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.015 · Cited by 197

Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine

Sindrup, S. H., Brøsen, K., Bjerring, P., Arendt-Nielsen, L., Larsen, U., Angelo, H. R., & Gram, L. F. (1990) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1990.212 · Cited by 194

Should We Use N -Acetyltransferase Type 2 Genotyping To Personalize Isoniazid Doses?

Kinzig-Schippers, M., Tomalik-Scharte, D., Jetter, A., Scheidel, B., Jakob, V., Rodamer, M., Cascorbi, I., Doroshyenko, O., Sörgel, F., & Fuhr, U. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.5.1733-1738.2005 · Cited by 194

Lipid-lowering response to statins is affected by CYP3A5 polymorphism

Kivistö, K. T., Niemi, M., Schaeffeler, E., Pitkälä, K., Tilvis, R., Fromm, M. F., Schwab, M., Eichelbaum, M., & Strandberg, T. (2004) · Pharmacogenetics · doi:10.1097/01.fpc.0000114762.78957.a5 · Cited by 193

Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine

Br�sen, K., Hansen, J. G., Nielsen, K. K., Sindrup, S. H., & Gram, L. F. (1993) · European Journal of Clinical Pharmacology · doi:10.1007/bf00316471 · Cited by 193

The Impact of Pharmacogenomics on Postoperative Nausea and Vomiting: Do CYP2D6 Allele Copy Number and Polymorphisms Affect the Success or Failure of Ondansetron Prophylaxis?

Candiotti, K. A., Birnbach, D. J., Lubarsky, D. A., Nhuch, F., Kamat, A., Koch, W. H., Nikoloff, M., Wu, L., & Andrews, D. (2005) · Anesthesiology · doi:10.1097/00000542-200503000-00011 · Cited by 193

CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation

Anglicheau, D. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.01.009 · Cited by 193

Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors

Wadelius, M., Sörlin, K., Wallerman, O., Karlsson, J., Yue, Q.-Y., Magnusson, P. K. E., Wadelius, C., & Melhus, H. (2004) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500220 · Cited by 191

Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis.

Parkin, D. P., Vandenplas, S., Botha, F. J., Vandenplas, M. L., Seifart, H. I., van Helden, P. D., van der Walt, B. J., Donald, P. R., & van Jaarsveld, P. P. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.155.5.9154882 · Cited by 190

Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype

Voora, D., Eby, C., Linder, M. W., Milligan, P. E., Bukaveckas, B. L., McLeod, H. L., Maloney, W., Clohisy, J., Burnett, S. R., Grosso, L., et al. (2005) · Thrombosis and Haemostasis · doi:10.1160/th04-08-0542 · Cited by 189

CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation

Goto, M., Masuda, S., Kiuchi, T., Ogura, Y., Oike, F., Okuda, M., Tanaka, K., & Inui, K.-I. (2004) · Pharmacogenetics · doi:10.1097/01.fpc.0000114747.08559.49 · Cited by 189

Gemfibrozil Inhibits CYP2C8-Mediated Cerivastatin Metabolism in Human Liver Microsomes

Wang, J.-S., Neuvonen, M., Wen, X., Backman, J. T., & Neuvonen, P. J. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.12.1352 · Cited by 189

Gemfibrozil considerably increases the plasma concentrations of rosiglitazone

Niemi, M., Backman, J. T., Granfors, M., Laitila, J., Neuvonen, M., & Neuvonen, P. J. (2003) · Diabetologia · doi:10.1007/s00125-003-1181-x · Cited by 186

Variability in human cytochrome P450 paclitaxel metabolism.

Sonnichsen, D. S., Liu, Q., Schuetz, E. G., Schuetz, J. D., Pappo, A., & Relling, M. V. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12102-2 · Cited by 186

Interphenotype differences in disposition and effect on gastrin levels of omeprazole—suitability of omeprazole as a probe for CYP2C19.

Chang, M., Tybring, G., Dahl, M., Gotharson, E., Sagar, M., Seensalu, R., & Bertilsson, L. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb04488.x · Cited by 184

Pharmacokinetics of losartan and its metabolite E‐3174 in relation to the CYP2C9 genotype

Yasar, Ü., Forslund‐Bergengren, C., Tybring, G., Dorado, P., LLerena, A., Sjöqvist, F., Eliasson, E., & Dahl, M. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.121216 · Cited by 183

Known variant DPYD alleles do not explain DPD deficiency in cancer patients

Collie-Duguid, E. S. R., Etienne, M. C., Milano, G., & McLeod, H. L. (2000) · Pharmacogenetics · doi:10.1097/00008571-200004000-00002 · Cited by 183

genotype–related efficacy of omeprazole for the treatment of infection caused by

TANIGAWARA, Y., AOYAMA, N., KITA, T., SHIRAKAWA, K., KOMADA, F., KASUGA, M., & OKUMURA, K. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70017-2 · Cited by 182

Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms*1

GARCIAMARTIN, E. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.04.006 · Cited by 182

Amitriptyline or Not, That Is the Question: Pharmacogenetic Testing of CYP2D6 and CYP2C19 Identifies Patients with Low or High Risk for Side Effects in Amitriptyline Therapy

Steimer, W., Zöpf, K., von Amelunxen, S., Pfeiffer, H., Bachofer, J., Popp, J., Messner, B., Kissling, W., & Leucht, S. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.041327 · Cited by 181

Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide

Niemi, M. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00228-5 · Cited by 181

Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone

Scordo, M. G., Spina, E., Facciolà, G., Avenoso, A., Johansson, I., & Dahl, M.-L. (1999) · Psychopharmacology · doi:10.1007/s002130051171 · Cited by 180

Preliminary phenotypic map of chromosome 4p16 based on 4p deletions

Estabrooks, L. L., Rao, K. W., Driscoll, D. A., Crandall, B. F., Dean, J. C. S., Ikonen, E., Korf, B., & Aylsworth, A. S. (1995) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320570413 · Cited by 179

Pharmacogenetics of Tolbutamide Metabolism in Humans

Scott, J., & Poffenbarger, P. L. (1978) · Diabetes · doi:10.2337/diab.28.1.41 · Cited by 179

Further Characterization of the Expression in Liver and Catalytic Activity of CYP2B6

Ekins, S., Vandenbranden, M., Ring, B. J., Gillespie, J. S., Yang, T. J., Gelboin, H. V., & Wrighton, S. A. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37719-5 · Cited by 178

Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver.

Lemoine, A., Gautier, J. C., Azoulay, D., Kiffel, L., Belloc, C., Guengerich, F. P., Maurel, P., Beaune, P., & Leroux, J. P. (1993) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13662-6 · Cited by 178

Role of the Smoking-Induced Cytochrome P450 (CYP)1A2 and Polymorphic CYP2D6 in Steady-State Concentration of Olanzapine

Carrillo, J. A., Herráiz, A. G., Ramos, S. I., Gervasini, G., Vizcaíno, S., & Benítez, J. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200304000-00003 · Cited by 177

Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat

van Beijsterveldt, L. E. C., Geerts, R. J. F., Leysen, J. E., Megens, A. A. H. P., Van den Eynde, H. M. J., Meuldermans, W. E. G., & Heykants, J. J. P. (1994) · Psychopharmacology · doi:10.1007/bf02245444 · Cited by 177

Pharmacogenetic determination of the effects of codeine and prediction of drug interactions.

Caraco, Y., Sheller, J., & Wood, A. J. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20766-2 · Cited by 176

Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol‐associated adverse effects

Wuttke, H., Rau, T., Heide, R., Bergmann, K., Böhm, M., Weil, J., Werner, D., & Eschenhagen, T. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.127111 · Cited by 175

Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities

Ward, S. A., Walle, T., Walle, U. K., Wilkinson, G. R., & Branch, R. A. (1989) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1989.11 · Cited by 174

Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects

Andersson, T., Reg??rdh, C.-G., Lou, Y.-C., Zhang, Y., Dahl, M.-L., & Bertilsson, L. (1992) · Pharmacogenetics · doi:10.1097/00008571-199202000-00005 · Cited by 173

Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes

Niemi, M., Cascorbi, I., Timm, R., Kroemer, H. K., Neuvonen, P. J., & Kivistö, K. T. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.127495 · Cited by 173

The Effects of Genetic Polymorphisms of CYP2C9 and CYP2C 19 on Phenytoin Metabolism in Japanese Adult Patients with Epilepsy: Studies in Stereoselective Hydroxylation and Population Pharmacokinetics

Mamiya, K., Ieiri, I., Shimamoto, J., Yukawa, E., Imai, J., Ninomiya, H., Yamada, H., Otsubo, K., Higuchi, S., & Tashiro, N. (1998) · Epilepsia · doi:10.1111/j.1528-1157.1998.tb01330.x · Cited by 173

Comparative Studies on the Catalytic Roles of Cytochrome P450 2C9 and Its Cys- and Leu-Variants in the Oxidation of Warfarin, Flurbiprofen, and Diclofenac by Human Liver Microsomes

Yamazaki, H., Inoue, K., Chiba, K., Ozawa, N., Kawai, T., Suzuki, Y., Goldstein, J. A., Guengerich, F. P., & Shimada, T. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00133-6 · Cited by 172

Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.

Kirchheiner, J., Bauer, S., Meineke, I., Rohde, W., Prang, V., Meisel, C., Roots, I., & Brockmöller, J. (2002) · Pharmacogenetics · doi:10.1097/00008571-200203000-00004 · Cited by 169

THE IMPORTANCE OF THIOPURINE METHYLTRANSFERASE ACTIVITY FOR THE USE OF AZATHIOPRINE IN TRANSPLANT RECIPIENTS1

Chocair, P. R., Duley, J. A., Simmonds, H. A., & Cameron, J. S. (1992) · Transplantation · doi:10.1097/00007890-199205000-00016 · Cited by 169

A Cost-Effectiveness Analysis of Alternative Disease Management Strategies in Patients with Crohn's Disease Treated with Azathioprine or 6-Mercaptopurine

Dubinsky, M. C., Reyes, E., Ofman, J., Chiou, C.-F., Wade, S., & Sandborn, W. J. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41900.x · Cited by 167

Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele

Kidd, R. S., Straughn, A. B., Meyer, M. C., Blaisdell, J., Goldstein, J. A., & Dalton, J. T. (1999) · Pharmacogenetics · doi:10.1097/00008571-199902000-00010 · Cited by 167

Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in luman beings

Dahl-Puustinen, M.-L., Lidén, A., Alm, C., Nordin, C., & Bertilsson, L. (1989) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1989.109 · Cited by 164

Cytochrome P450 Phenotyping/Genotyping in Patients Receiving Antipsychotics: Useful Aid to Prescribing?

Dahl, M.-L. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241070-00001 · Cited by 163

The activation of the biguanide antimalarial proguanil co‐segregates with the mephenytoin oxidation polymorphism‐a panel study.

Ward, S., Helsby, N., Skjelbo, E., Brosen, K., Gram, L., & Breckenridge, A. (1991) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1991.tb05594.x · Cited by 163

Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation

TURPEINEN, M., TOLONEN, A., UUSITALO, J., JALONEN, J., PELKONEN, O., & LAINE, K. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.02.010 · Cited by 163

Impaired oxidation of debrisoquine in patients with perhexiline liver injury.

Morgan, M. Y., Reshef, R., Shah, R. R., Oates, N. S., Smith, R. L., & Sherlock, S. (1984) · Gut · doi:10.1136/gut.25.10.1057 · Cited by 163

Pharmacokinetics of voriconazole and cytochrome p450 2C19 genetic status

IKEDA, Y. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.02.002 · Cited by 162

Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes

Takahashi, H., Kashima, T., Nomoto, S., Iwade, K., Tainaka, H., Shimizu, T., Nomizo, Y., Muramoto, N., Kimura, S., & Echizen, H. (1998) · Pharmacogenetics · doi:10.1097/00008571-199810000-00001 · Cited by 162

Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease

Gearry, R. B., Barclay, M. L., Burt, M. J., Collett, J. A., & Chapman, B. A. (2004) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.926 · Cited by 159

Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study

�gren, H., Bertilsson, L., Kawanishi, C., & Lundgren, S. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0701-4 · Cited by 159

Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent.

Cole, P. L., Beamer, A. D., McGowan, N., Cantillon, C. O., Benfell, K., Kelly, R. A., Hartley, L. H., Smith, T. W., & Antman, E. M. (1990) · Circulation · doi:10.1161/01.cir.81.4.1260 · Cited by 159

Frequency and type of reactions to antituberculosis drugs: Observations in routine treatment

Ormerod, L. P., & Horsfield, N. (1996) · Tubercle and Lung Disease · doi:10.1016/s0962-8479(96)90073-8 · Cited by 158

Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype

von Bahr, C., Movin, G., Nordin, C., Lidén, A., Hammarlund-Udenaes, M., Hedberg, A., Ring, H., & Sjöqvist, F. (1991) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1991.22 · Cited by 158

Contributions of Five Human Cytochrome P450 Isoforms to the N‐demethylation of Clozapine In Vitro at Low and High Concentrations

Olesen, O. V., & Línnet, K. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122010717 · Cited by 158

Cost‐effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease

Winter, J., Walker, A. W., Shapiro, D., Gaffney, D., Spooner, R. J., & Mills, P. R. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02124.x · Cited by 157

Haloperidol Disposition Is Dependent on Debrisoquine Hydroxylation Phenotype

LLerena, A., Alm, C., Dahl, M., Ekqvist, B., & Bertilsson, L. (1992) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199204000-00003 · Cited by 156

Olsalazine and 6-mercaptopurine-related bone marrow suppression: A possible drug-drug interaction

Lewis, L. D., Benin, A., Szumlanski, C. L., et al. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90125-9 · Cited by 156

Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease

Cuffari, C., Dassopoulos, T., Turnbough, L., Thompson, R. E., & Bayless, T. M. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00127-2 · Cited by 156

Metoprolol metabolism and debrisoquine oxidation polymorphism‐ population and family studies.

McGourty, J. C., Silas, J., Lennard, M., et al. (1985) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1985.tb05112.x · Cited by 155

Five Distinct Human Cytochromes Mediate Amitriptyline N‐DemethylationIn Vitro: Dominance of CYP 2C19 and 3A4

Venkatakrishnan, K., Greenblatt, D. J., Moltke, L. L., et al. (1998) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1998.tb04399.x · Cited by 155

Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy*

ODANI, A., Hashimoto, Y., OTSUKI, Y., et al. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90031-x · Cited by 154

Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole

Furuta, T., Shirai, N., Watanabe, F., Honda, S., Takeuchi, K., Iida, T., Sato, Y., Kajimura, M., Futami, H., Takayanagi, S., et al. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.127637 · Cited by 153

Disposition and Metabolic Fate of Atomoxetine Hydrochloride: The Role of CYP2D6 in Human Disposition and Metabolism

Sauer, J., Ponsler, G. D., Mattiuz, E. L., Long, A. J., Witcher, J. W., Thomasson, H. R., & DESANTE, K. A. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.1.98 · Cited by 152

Role of CYP2C9 polymorphism in losartan oxidation.

Yaşar, Ü., Tybring, G., Hidestrand, M., Oscarson, M., Ingelman‐Sundberg, M., Dahl, M. L., & Eliasson, E. (2001) · PubMed · Cited by 151

Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: Nonlinearity and relation to the sparteine oxidation polymorphism

Sindrup, S. H., Brøsen, K., & Gram, L. F. (1992) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1992.24 · Cited by 151

Hepatic toxicity in south indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide

Parthasarathy, R., Sarma, G. R., Janardhanam, B., Ramachandran, P., Santha, T., Sivasubramanian, S., Somasundaram, P. R., & Tripathy, S. P. (1986) · Tubercle · doi:10.1016/0041-3879(86)90003-6 · Cited by 150

Characterization of CYP2C19 and CYP2C9 from Human Liver: Respective Roles in Microsomal Tolbutamide,S-Mephenytoin, and Omeprazole Hydroxylations

Lasker, J. M., Wester, M. R., Aramsombatdee, E., & Raucy, J. L. (1998) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1998.0615 · Cited by 150

Safe treatment of thiopurine S-methyltransferase deficient Crohn’s disease patients with azathioprine

Kaskas, B., Louis, E., Hindorf, U., Schaeffeler, E., Deflandre, J., Graepler, F., Schmiegelow, K., Gregor, M., Zanger, U. M., Eichelbaum, M., et al. (2002) · Gut · doi:10.1136/gut.52.1.140 · Cited by 150

In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol.

Oldham, H. G., & Clarke, S. E. (1997) · PubMed · Cited by 150

Tacrolimus Dosing in Adult Lung Transplant Patients Is Related to Cytochrome P4503A5 Gene Polymorphism

Zheng, H., Zeevi, A., Schuetz, E. G., Lamba, J. K., McCurry, K. R., Griffith, B. P., Webber, S., Ristich, J., Dauber, J. H., Iacono, A. T., et al. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003262108 · Cited by 149

The 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Fluvastatin: Effect on Human Cytochrome P-450 and Implications for Metabolic Drug Interactions

Fischer, V., Johanson, L., Heitz, F., Tullman, R. H., Graham, E., Baldeck, J. P., & Robinson, W. T. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14919-7 · Cited by 149

Identification of the human P450 enzymes involved in lansoprazole metabolism.

Pearce, R. E., Rodrigues, A. D., Goldstein, J. A., et al. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12938-8 · Cited by 148

Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19

Wang, J., Liu, Z., Wang, W., Chen, X., Shu, Y., He, N., & Zhou, H. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.116513 · Cited by 147

Cytochrome P450 3A and their regulation

Burk, O., & Wojnowski, L. (2004) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-003-0815-3 · Cited by 147

Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents

Holstein, A., Plaschke, A., Ptak, M., Egberts, E. ‐., El-Din, J. S., Brockmöller, J., & Kirchheiner, J. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02379.x · Cited by 146

CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole

Adachi, K., Katsube, T., Kawamura, A., et al. (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00840.x · Cited by 144

Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype

Hillman, M. A., Wilke, R. A., Caldwell, M. D., Berg, R. L., Glurich, I., & Burmester, J. K. (2004) · Pharmacogenetics · doi:10.1097/01.fpc.0000114760.08559.dc · Cited by 144

Differential expression and function of CYP2C isoforms in human intestine and liver

pple, F. L., von Richter, O., Fromm, M. F., Richter, T., Thon, K. P., Wisser, H., Griese, E., Eichelbaum, M. F., & Kivist, K. T. (2003) · Pharmacogenetics · doi:10.1097/00008571-200309000-00005 · Cited by 144

D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate

Nyberg, S., Farde, L., Halldin, C., Dahl, M., & Bertilsson, L. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.2.173 · Cited by 143

A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome

Wolkenstein, P., Carri??re, V., Charue, D., Bastuji-Garin, S., Revuz, J., Roujeau, J.-C., Beaune, P., & Bagot, M. (1995) · Pharmacogenetics · doi:10.1097/00008571-199508000-00011 · Cited by 143

FAMILIAL INCIDENCE OF LOW PSEUDOCHOLINESTERASE LEVEL

KALOW, W. (1956) · The Lancet · doi:10.1016/s0140-6736(56)92065-7 · Cited by 143

CYP2D6 Inhibition by Fluoxetine, Paroxetine, Sertraline, and Venlafaxine in a Crossover Study: Intraindividual Variability and Plasma Concentration Correlations

Alfaro, C. L., Lam, Y. W. F., Simpson, J., & Ereshefsky, L. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/009127000004000108 · Cited by 142

The Second Generation of COX-2 Inhibitors: What Advantages Do the Newest Offer?

Stichtenoth, D. O., & lich, J. R. C. F. (2003) · Drugs · doi:10.2165/00003495-200363010-00003 · Cited by 142

Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity

Hamelin, B. A. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.106464 · Cited by 141

The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine

Skjelbo, E., Brøsen, K., Hallas, J., et al. (1991) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1991.4 · Cited by 141

Allele-Specific Change of Concentration and Functional Gene Dose for the Prediction of Steady-State Serum Concentrations of Amitriptyline and Nortriptyline in CYP2C19 and CYP2D6 Extensive and Intermediate Metabolizers

Steimer, W., Zöpf, K., von Amelunxen, S., Pfeiffer, H., Bachofer, J., Popp, J., Meßner, B., Kissling, W., & Leucht, S. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2003.030825 · Cited by 141

Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population.

Sohn, D., Kobayashi, K., Chiba, K., Lee, K., Shin, S. G., & Ishizaki, T. (1992) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10918-x · Cited by 140

Pharmacogenetics of tolbutamide metabolism in humans

Scott, J., & Pl, P. (1979) · Diabetes · doi:10.2337/diabetes.28.1.41 · Cited by 139

Pharmacokinetics of Midazolam and 1′-Hydroxymidazolam in Chinese with Different CYP3A5 Genotypes

Shih, P.-S., & Huang, J. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.12.1491 · Cited by 138

Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double‐blind cross‐over study.

Sindrup, S. H., Gram, L. F., Skjold, T., Grodum, E., Brøsen, K., & Beck‐Nielsen, H. (1990) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1990.tb03836.x · Cited by 138

Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine.

Marra, C. A., Esdaile, J. M., & Anis, A. H. (2002) · PubMed · Cited by 137

Comparative Efficacy of Antidepressants

Kasper, S. F., Fuger, J., & Möller, H. ‐. (1992) · Drugs · doi:10.2165/00003495-199200432-00004 · Cited by 137

Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status

Yasuda, S., Horai, Y., Tomono, Y., Nakai, H., Yamato, C., Manabe, K., Kobayashi, K., Chiba, K., & Ishizaki, T. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90192-2 · Cited by 137

Venlafaxine Serum Levels and CYP2D6 Genotype

Veefkind, A. H., Haffmans, P. M. J., & Hoencamp, E. (2000) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200004000-00011 · Cited by 136

The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels

Kerb, R., Aynacioglu, A. S., Brockmöller, J., Schlagenhaufer, R., Bauer, S., Szekeres, T., Hamwi, A., Fritzer-Szekeres, M., Baumgärtner, C., Ongen, H. Z., et al. (2001) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500025 · Cited by 135

Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin

Furuta, T., Shirai, N., Takashima, M., Fang, X., Hanai, H., Nakagawa, K., Sugimura, H., Ohashi, K., & Ishizaki, T. (2001) · Pharmacogenetics · doi:10.1097/00008571-200106000-00009 · Cited by 134

Identification of Cytochrome P450 Isoforms Involved in Citalopram N-Demethylation by Human Liver Microsomes

Kobayashi, K., Chiba, K., Yagi, T., Shimada, N., Taniguchi, T., Horie, T., Tani, M., Yamamoto, T., Ishizaki, T., & Kuroiwa, Y. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36462-6 · Cited by 134

(R)-, (S)-, and Racemic Fluoxetine N-Demethylation by Human Cytochrome P450 Enzymes

Margolis, J. M., O’Donnell, J. P., Mankowski, D. C., Ekins, S., & Obach, R. S. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12048-2 · Cited by 134

Identification of the Human Cytochromes P450 Responsible for Atomoxetine Metabolism

Ring, B. J., Gillespie, J. S., Eckstein, J. A., & Wrighton, S. A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.3.319 · Cited by 133

In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration

Lin, Y. S., Lockwood, G. F., Graham, M. A., Brian, W. R., Loi, C., Dobrinska, M. R., Shen, D. D., Watkins, P. B., Wilkinson, G. R., Kharasch, E. D., et al. (2001) · Pharmacogenetics · doi:10.1097/00008571-200112000-00006 · Cited by 133

The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes.

Bloomer, J. C., Woods, F. R., Haddock, R. E., Lennard, M., & Tucker, G. (1992) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1992.tb04082.x · Cited by 133

Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage

Wilke, R. A., Moore, J. H., & Burmester, J. K. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01213011-200506000-00007 · Cited by 133

The Role of Genetically Determined Polymorphic Drug Metabolism in the Beta-Blockade Produced by Propafenone

Lee, J. T., Kroemer, H. K., Silberstein, D. J., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199006213222502 · Cited by 132

Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone: Effect of Comedication With Carbamazepine or Valproate

Spina, E., Avenoso, A., Facciolà, G., Salemi, M., Scordo, M. G., Giacobello, T., Madia, A. G., & Perucca, E. (2000) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200008000-00019 · Cited by 132

Metabolism of pyrimidine analogues and their nucleosides

Daher, G. C., Harris, B., & Diasio, R. B. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90080-l · Cited by 131

Stereoselective disposition of carvedilol is determined by CYP2D6*

Zhou, H.-H., & Wood, A. J. J. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90036-5 · Cited by 131

Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine.

Yue, Q.-Y., Hasselström, J., Svensson, J., & Säwe, J. (1991) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1991.tb05585.x · Cited by 130

Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use

Martínez, C., Blanco‐Fernández, G., Ladero, J. M., García‐Martín, E., Taxonera, C., Garcia-Gamito, F. J., Díaz‐Rubio, M., & Agúndez, J. A. G. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705623 · Cited by 130

CYP2D6genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects

Gießmann, T., Modeß, C., Hecker, U., Zschiesche, M., Dazert, P., Kunert‐Keil, C., Warzok, R., Engel, G., Weitschies, W., Cascorbi, I., et al. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.10.004 · Cited by 130

An Improved Cocaine Hydrolase: The A328Y Mutant of Human Butyrylcholinesterase is 4-fold More Efficient

Xie, W., Altamirano, C. V., Bartels, C. F., Speirs, R. J., Cashman, J. R., & Lockridge, O. (1999) · Molecular Pharmacology · doi:10.1124/mol.55.1.83 · Cited by 130

Safety profile of atomoxetine in the treatment of children and adolescents with ADHD.

Wernicke, J. F., & Kratochvil, C. J. (2002) · PubMed · Cited by 128

Sertraline N-Demethylation Is Catalyzed by Multiple Isoforms of Human Cytochrome P-450 In Vitro

Kobayashi, K., Ishizuka, T., Shimada, N., Yoshimura, Y., Kamijima, K., & Chiba, K. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15222-1 · Cited by 127

Thiopurine methyltransferase polymorphic tandem repeat: Genotype-phenotype correlation analysis

Li, Y. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.108674 · Cited by 127

Untitled work

Bardsley-Elliot (2000) · doi:10.2165/00003495-200059030-00014 · Cited by 127

The Analgesic Effect of Tramadol After Intravenous Injection in Healthy Volunteers in Relation to CYP2D6

Enggaard, T. P., Poulsen, L. K., Arendt‐Nielsen, L., Brøsen, K., Ossig, J., & Sindrup, S. H. (2005) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000189613.61910.32 · Cited by 126

Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (−)-3s,5r-fluvastatin and (+)-3r,5s-fluvastatin in healthy volunteers

Kirchheiner, J. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00121-8 · Cited by 126

Impact of genotype on adverse effects during treatment with metoprolol: A prospective clinical study

Fux, R., Mörike, K., Pröhmer, A. M. T., Delabar, U., Schwab, M. G., Schaeffeler, E., LORENZ, G., Gleiter, C. H., Eichelbaum, M. F., & Kivistö, K. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.07.004 · Cited by 126

Metabolism of the Antidepressant Mirtazapine in Vitro: Contribution of Cytochromes P-450 1A2, 2D6, and 3A4

Stürmer, E., Moltke, L. L., Shader, R. I., & Greenblatt, D. J. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12045-7 · Cited by 126

Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease

Inter, J. W. (2004) · Cited by 126

Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole

Andersson, T., Holmberg, J., Rohss, K. M., & Walan, A. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.t01-1-00702.x · Cited by 125

Clinical Pharmacokinetics of Cerivastatin

ck, W. M. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200039020-00002 · Cited by 124

IN VITRO CHARACTERIZATION OF CLOBAZAM METABOLISM BY RECOMBINANT CYTOCHROME P450 ENZYMES: IMPORTANCE OF CYP2C19

Giraud, C., Tran, A., Rey, E., Vincent, J., Tréluyer, J., & Pons, G. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.11.1279 · Cited by 123

CYP2C19 Genotype and Pharmacokinetics of Three Proton Pump Inhibitors in Healthy Subjects

Sakai, T., Aoyama, N., Kita, T., Sakaeda, T., Nishiguchi, K., Nishitora, Y., Hohda, T., Shirasaka, D., Tamura, T., Tanigawara, Y., et al. (2001) · Pharmaceutical Research · doi:10.1023/a:1011035007591 · Cited by 122

N‐Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity.

Gill, H., Tingle, M. D., & Park, B. K. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb05797.x · Cited by 121

Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans*

Furuta, T., Ohashi, K., Kobayashi, K., et al. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70034-2 · Cited by 121

Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2

Kirchheiner, J., Meineke, I., Freytag, G. T. H., Meisel, C., Roots, I., & Brockmöller, J. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.125726 · Cited by 120

Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics

Sohn, D., Kusaka, M., Ishizaki, T., et al. (1992) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1992.125 · Cited by 119

Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone

Jaakkola, T., Backman, J. T., Neuvonen, M., & Neuvonen, P. J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.12.266 · Cited by 119

Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes

Horai, Y., Kimura, M., Furuie, H., Matsuguma, K., Irie, S., Koga, Y., Nagahama, T., Murakami, M., Matsui, T., Yao, T., et al. (2001) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2001.00980.x · Cited by 118

Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites

Kirchheiner, J., St??rmer, E., Meisel, C., Steinbach, N., Roots, I., & ller, J. R. B. (2003) · Pharmacogenetics · doi:10.1097/00008571-200308000-00005 · Cited by 118

Human thiopurine methyltransferase pharmacogenetics. Kindred with a terminal exon splice junction mutation that results in loss of activity.

Otterness, D. M., Szumlanski, C. L., Wood, T. C., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1004 · Cited by 118

Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population.

Gross, M. D., Kruisselbrink, T., Anderson, K. E., Lang, N. P., McGovern, P. G., Delongchamp, R. R., & Kadlubar, F. F. (1999) · PubMed · Cited by 117

A double-blind comparison of intensive course 5-fluorouracil by oral vs. intravenous route in the treatment of colorectal carcinoma

Hahn, R. G., Moertel, C. G., Schutt, A. J., & Bruckner, H. W. (1975) · Cancer · Cited by 116

Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine*

Brynne, N., Dalén, P., Alván, G., Bertilsson, L., & Gabrielsson, J. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90104-7 · Cited by 116

The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro

Yaşar, Ü., Eliasson, E., Forslund‐Bergengren, C., Tybring, G., Gadd, M., Sjöqvist, F., & Dahl, M. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-001-0376-7 · Cited by 115

Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate.

Ho, D. H., Townsend, L. B., Luna, M. A., & Bodey, G. P. (1986) · PubMed · Cited by 114

The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide

Niemi, M., Neuvonen, P. J., & Kivistö, K. T. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.116511 · Cited by 113

Stereoselective disposition and pharmacologic activity of propafenone enantiomers.

Kroemer, H. K., Funck‐Brentano, C., Silberstein, D. J., Wood, A. J., Eichelbaum, M. F., Woosley, R. L., & Roden, D. M. (1989) · Circulation · doi:10.1161/01.cir.79.5.1068 · Cited by 113

The Gastroprokinetic and Antiemetic Drug Metoclopramide Is a Substrate and Inhibitor of Cytochrome P450 2D6

Desta, Z., Wu, G. M., Morocho, A. M., & Flockhart, D. A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.3.336 · Cited by 113

The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin*

Hamelin, B. A., Turgeon, J., Vallée, F., Bélanger, P.-M., Paquet, F., & LeBel, M. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90147-2 · Cited by 112

Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction

Yasar, ?., Bennet, A. M., Eliasson, E., Lundgren, S., Wiman, B., Fairé, U. D., & Rane, A. (2003) · Pharmacogenetics · doi:10.1097/00008571-200312000-00002 · Cited by 111

Influence of Drugs Interacting with CYP3A4 on the Pharmacokinetics, Pharmacodynamics, and Safety of the Prandial Glucose Regulator Repaglinide

Hatorp, V., Hansen, K. T., & Thomsen, M. S. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003253704 · Cited by 110

Serum Concentrations and Side Effects in Psychiatric Patients During Risperidone Therapy

Olesen, O. V., Licht, R. W., Thomsen, E., et al. (1998) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199808000-00004 · Cited by 110

Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase

Sandberg, M., Yaşar, Ü., Strömberg, P., Höög, J., & Eliasson, E. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01660.x · Cited by 109

Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis.

Grönhagen-Riska, C., Hellström, P. E., & Fröseth, B. (1978) · PubMed · doi:10.1164/arrd.1978.118.3.461 · Cited by 109

Dosage Recommendation of Phenytoin for Patients with Epilepsy with Different CYP2C9/CYP2C19 Polymorphisms

Hung, C., Lin, C., Chen, C., Chang, C., & Liou, H. (2004) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200410000-00012 · Cited by 109

Characterization of cytochrome P-450 2B6 in human liver microsomes.

Mimura, M., Baba, T., Yamazaki, H., Ohmori, S., Inui, Y., Gonzalez, F. J., Guengerich, F. P., & Shimada, T. (1993) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08198-x · Cited by 109

Fluorouracil Therapy in Patients With Carcinoma of the Large Bowel

Christophidis, N., Vajda, F. J. E., Lucas, I., et al. (1978) · Clinical Pharmacokinetics · doi:10.2165/00003088-197803040-00006 · Cited by 106

Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration.

Os, E. C. V., Zins, B., Sandborn, W. J., Mays, D. C., Tremaine, W. J., Mahoney, D. W., Zinsmeister, A. R., & Lipsky, J. J. (1996) · Gut · doi:10.1136/gut.39.1.63 · Cited by 106

Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects

Schröder, H., & Evans, D. A. P. (1972) · Gut · doi:10.1136/gut.13.4.278 · Cited by 105

Polymorphisms in the CYP 2D6 Gene: Association with Plasma Concentrations of Fluoxetine and Paroxetine

Charlier, C., Broly, F., Lhermitte, M., Pinto, E., Ansseau, M., & Plomteux, G. J. (2003) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200312000-00014 · Cited by 105

Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity

Pirmohamed, M., Alfirevic, A., Vilar, J., Stalford, A. C., Wilkins, E., Sim, E., & Park, B. K. (2000) · Pharmacogenetics · doi:10.1097/00008571-200011000-00005 · Cited by 105

Influence ofCYP2C9, 2C19and2D6Genetic Polymorphisms on the Steady‐State Plasma Concentrations of the Enantiomers of Fluoxetine and Norfluoxetine

Scordo, M. G., Spina, E., Dahl, M., Gatti, G., & Perucca, E. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto_194.x · Cited by 104

Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states*1

YU, K. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.03.009 · Cited by 104

Effect of the gene dosage of on diazepam metabolism in Chinese subjects

QIN, X., Xie, H., Wang, W., HE, N., Huang, S., Xu, Z., Ouyang, D., WANG, Y., & Zhou, H.-W. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1053/cp.1999.v66.103379001 · Cited by 103

A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin

Rettie, A. E., Haining, R. L., Bajpai, M., et al. (1999) · Epilepsy Research · doi:10.1016/s0920-1211(99)00017-0 · Cited by 103

Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study

Spina, E., Gitto, C., Avenoso, A., Campo, G. M., Caputi, A. P., & Perucca, E. (1997) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050220 · Cited by 103

Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours

McLeod, H. L., Sludden, J., Murray, G. I., Keenan, R. A., Davidson, A., Park, K., Koruth, M., & Cassidy, J. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.73 · Cited by 103

Low‐dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. a twenty‐four—week controlled clinical trial

Hamdy, H., McKendry, R. J. R., Mierins, E., & Liver, J. A. (1987) · Arthritis & Rheumatism · doi:10.1002/art.1780300401 · Cited by 103

Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism

Br�sen, K., Klysner, R., Gram, L. F., Otton, S. V., Bech, P., & Bertilsson, L. (1986) · European Journal of Clinical Pharmacology · doi:10.1007/bf00608215 · Cited by 102

Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans

Kirchheiner, J., Meineke, I., Steinbach, N., Meisel, C., Roots, I., & Brockmöller, J. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01712.x · Cited by 102

The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon

Visser, L. E., van Vliet, M., van Schaik, R. H., Kasbergen, A. A. H., Smet, P. A. G. M. D., Vulto, A. G., Albert Hofman, D., van Duijn, C. M., & Stricker, B. H. C. (2003) · Pharmacogenetics · doi:10.1097/00008571-200401000-00003 · Cited by 101

The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol*

Jerling, M., Dahl, M., Åberg‐Wistedt, A., et al. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90111-3 · Cited by 100

Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients

Andreassen, O. A., MacEwan, T., Gulbrandsen, A.-K., et al. (1997) · Psychopharmacology · doi:10.1007/s002130050281 · Cited by 100

Imipramine demethylation and hydroxylation: Impact of the sparteine oxidation phenotype

Brøsen, K., Otton, S. V., & Gram, L. F. (1986) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1986.221 · Cited by 100

CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy*1

WONG, M. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.02.005 · Cited by 100

Adverse Reactions to Sulfisoxazole, Sulfamethoxazole, and Nitrofurantoin

Koch‐Weser, J. (1971) · Archives of Internal Medicine · doi:10.1001/archinte.1971.00310210075006 · Cited by 100

The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine

FJORDSIDE, L., Jeppesen, U., Eap, C. B., Powell, K., Baumann, P., & Brossen, K. (1999) · Pharmacogenetics · doi:10.1097/00008571-199902000-00008 · Cited by 100

Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study*

Gram, L. F., Guentert, T. W., Grange, S., Vistisen, K. K., & Brøsen, K. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90230-9 · Cited by 100

CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis

Patsopoulos, N. A., Ntzani, E., Zintzaras, E., & Ioannidis, J. P. A. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01213011-200503000-00003 · Cited by 99

Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers

Fukuda, T., Yamamoto, I., Nishida, Y., Zhou, Q., Ohno, M., Takada, K., & Azuma, J. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00913.x · Cited by 98

Haloperidol Disposition Is Dependent on the Debrisoquine Hydroxylation Phenotype

LLerena, A., Dahl, M., Ekqvist, B., et al. (1992) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199206000-00014 · Cited by 98

Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.

Bocci, G., Danesi, R., Paolo, A. D., et al. (2000) · PubMed · Cited by 98

Skin cancer in renal transplant recipients is associated with increased concentrations of 6-thioguanine nucleotide in red blood cells

Lennard, L., THOMAS, S., HARRINGTON, C. I., & Maddocks, J. L. (1985) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1985.tb02408.x · Cited by 97

CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of

Schwab, M. G., Schaeffeler, E., Klotz, U. E., & Treiber, G. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.05.002 · Cited by 97

Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes

Herrlin, K., Yasui‐Furukori, N., Tybring, G., Widén, J., Gustafsson, L. L., & Bertilsson, L. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01874.x · Cited by 96

Pharmacokinetic-Pharmacodynamic Profile of Angiotensin II Receptor Antagonists

Csajka, C., Buclin, T., Brunner, H. R., & Biollaz, J. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732010-00001 · Cited by 96

BURNS FROM MICROWAVE OVENS

Maley, M. (1986) · The Lancet · doi:10.1016/s0140-6736(86)91853-2 · Cited by 96

Identification of the Human Cytochromes P450 Responsible for in Vitro Formation of R- and S-Norfluoxetine

Ring, B. J., Eckstein, J. A., Gillespie, J. S., et al. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29631-2 · Cited by 96

Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype

Armstrong, M., Daly, A. K., Blennerhassett, R. C., Ferrier, N., & Idle, J. R. (1997) · The British Journal of Psychiatry · doi:10.1192/bjp.170.1.23 · Cited by 96

Pharmacoeconomic Analyses of Azathioprine, Methotrexate and Prospective Pharmacogenetic Testing for the Management of Inflammatory Bowel Disease

Priest, V., Begg, E. J., Gardiner, S. J., FRAMPTON, C. M. A., Gearry, R. B., Barclay, M. L., Clark, D. W. J., & Hansen, P. (2006) · PharmacoEconomics · doi:10.2165/00019053-200624080-00004 · Cited by 95

Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers

Hemeryck, A., Lefebvre, R. A., DEVRIENDT, C., & Belpaire, F. M. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.104788 · Cited by 95

Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans.

Eap, C. B., Lessard, E., Baumann, P., Brawand-Amey, M., Yessine, M., O’Hara, G. E., & Turgeon, J. (2003) · Pharmacogenetics · doi:10.1097/00008571-200301000-00006 · Cited by 95

The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron.

Fischer, V., Vickers, A. E. M., Heitz, F., et al. (1994) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08368-0 · Cited by 95

Azelastine N-Demethylation by Cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in Human Liver Microsomes: Evaluation of Approach to Predict the Contribution of Multiple CYPs

Nakajima, M., Nakamura, S., Tokudome, S., Shimada, N., Yamazaki, H., & Yokoi, T. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14947-1 · Cited by 94

The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways.

Nielsen, K. K., Flinois, J. P., Beaune, P. H., et al. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13120-0 · Cited by 94

Effect of Potent CYP2D6 Inhibition by Paroxetine on Atomoxetine Pharmacokinetics

Belle, D. J., Ernest, C. S., Sauer, J., Smith, B. P., Thomasson, H. R., & Witcher, J. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/009127002762491307 · Cited by 94

Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients

Carr, A. D., Gross, A. S., Hoskins, J. M., Penny, R., & Cooper, D. A. (1994) · AIDS · doi:10.1097/00002030-199403000-00006 · Cited by 94

Nortriptyline E‐10‐Hydroxylation in Vitro Is Mediated by Human CYP2D6 (High Affinity) and CYP3A4 (Low Affinity): Implications for Interactions with Enzyme‐Inducing Drugs

Venkatakrishnan, K., Moltke, L. L., & Greenblatt, D. J. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922008173 · Cited by 94

Diazepam metabolism by cDNA-expressed human 2C P450s: identification of P4502C18 and P4502C19 as low K(M) diazepam N-demethylases.

Jung, F., Richardson, T. H., Raucy, J. L., & Johnson, E. F. (1997) · PubMed · Cited by 94

Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo

Fuller, R. W. (1992) · Neuropharmacology · doi:10.1016/0028-3908(92)90100-4 · Cited by 93

The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population

Fukuda, T., Nishida, Y., Zhou, Q., Yamamoto, I., Kondo, S., & Azuma, J. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050737 · Cited by 93

The Effect of Thiopurine Methyltransferase Expression on Sensitivity to Thiopurine Drugs

Coulthard, S. A., Hogarth, L., Little, M., Matheson, E. C., Redfern, C. P. F., Minto, L., & Hall, A. G. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.1.102 · Cited by 92

Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects

Eap, C. B., Buclin, T., Hustert, E., Bleiber, G., Golay, K. P., Aubert, A.-C., Baumann, P., Telenti, A., & Kerb, R. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0767-7 · Cited by 91

Single-dose kinetics of clomipramine: Relationship to the sparteine and S-mephenytoin oxidation polymorphisms

Nielsen, K. K., Brøsen, K., Hansen, M. G. J., & Gram, L. F. (1994) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1994.65 · Cited by 91

The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon

Visser, L. E., van Schaik, R. H., van Vliet, M., et al. (2004) · Thrombosis and Haemostasis · doi:10.1160/th03-12-0741 · Cited by 91

Low daily 10‐mg and 20‐mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19)

Christensen, M., Tybring, G., Mihara, K., Yasui‐Furokori, N., Carrillo, J. A., Ramos, S., Andersson, K., Dahl, M., & Bertilsson, L. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.121788 · Cited by 90

Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects

Moltke, L. L., Greenblatt, D. J., Grassi, J. M., et al. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00353-9 · Cited by 90

Identification of a novel variant CYP2C9 allele in Chinese

Si, D., Guo, Y., Zhang, Y., et al. (2004) · Pharmacogenetics · doi:10.1097/01.fpc.0000114749.08559.e4 · Cited by 90

Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.

Laine, K., Tybring, G., Härtter, S., et al. (2001) · PubMed · Cited by 89

Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotype status*

Sohn, D., Kwon, J., Kim, H.-K., & Ishizaki, T. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90137-5 · Cited by 89

Role of CYP2B6 and CYP3A4 in the In Vitro N-Dechloroethylation of (R)- and (S)-Ifosfamide in Human Liver Microsomes

Granvil, C. P., Madan, A., Sharkawi, M., et al. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15217-8 · Cited by 89

Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation

Zanger, U. M., Turpeinen, M., Klein, K., & Schwab, M. (2008) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-008-2291-6 · Cited by 593

Pharmacokinetics

Fan, J., & de Lannoy, I. A. M. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.09.007 · Cited by 309

Sex-specific differences in CYP450 isoforms in humans

Scandlyn, M. J., Stuart, E. C., & Rosengren, R. J. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.4.413 · Cited by 199

Pharmacogenetics and Pain Treatment with a Focus on Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Antidepressants: A Systematic Review

Zobdeh, F., Eremenko, I. I., Akan, M. A., Tarasov, V. V., Chubarev, V. N., Schiöth, H. B., & Mwinyi, J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061190 · Cited by 45

Integument

Diegel, K. L., Danilenko, D. M., & Wojcinski, Z. W. (2013) · Haschek and Rousseaux's Handbook of Toxicologic Pathology · doi:10.1016/b978-0-12-415759-0.00055-8 · Cited by 6